Coppell Advisory Solutions LLC Sells 9,113 Shares of AstraZeneca PLC $AZN

Key Points

• Coppell Advisory Solutions LLC has reduced its stake in AstraZeneca PLC by 27.4%, selling 9,113 shares and holding 24,117 shares worth approximately $1.73 million as of the latest SEC filing.
• Other institutional investors have also increased their stakes in AstraZeneca, including Goldman Sachs which raised its stake by 30.9% to over $1 billion, and Boston Partners which increased by 35.9%.
• AstraZeneca's recent quarterly earnings met analysts' expectations at $1.09 EPS, with revenues of $14.46 billion—an increase of 16.1% year-over-year.

Coppell Advisory Solutions LLC reduced its stake in AstraZeneca PLC (NASDAQ:AZN - Free Report) by 27.4% in the first quarter, according to its most recent Form 13F filing with the Securities and Exchange Commission (SEC). The firm owned 24,117 shares of the company's stock after selling 9,113 shares during the period. Coppell Advisory Solutions LLC's holdings in AstraZeneca were worth $1,729,000 at the end of the most recent reporting period.

Other large investors have also recently made changes to their positions in the company. Goldman Sachs Group Inc. lifted its stake in AstraZeneca by 30.9% during the first quarter. Goldman Sachs Group Inc. now owns 13,647,948 shares of the company's stock worth $1,003,124,000 after purchasing an additional 3,224,251 shares during the last quarter. Boston Partners lifted its stake in AstraZeneca by 35.9% during the first quarter. Boston Partners now owns 5,036,645 shares of the company's stock worth $368,712,000 after purchasing an additional 1,329,166 shares during the last quarter. Ameriprise Financial Inc. lifted its stake in AstraZeneca by 5.6% during the first quarter. Ameriprise Financial Inc. now owns 4,942,367 shares of the company's stock worth $364,283,000 after purchasing an additional 261,064 shares during the last quarter. WCM Investment Management LLC lifted its stake in AstraZeneca by 7.3% during the first quarter. WCM Investment Management LLC now owns 4,003,070 shares of the company's stock worth $295,387,000 after purchasing an additional 272,537 shares during the last quarter. Finally, Invesco Ltd. lifted its stake in AstraZeneca by 33.2% during the first quarter. Invesco Ltd. now owns 3,807,522 shares of the company's stock worth $279,853,000 after purchasing an additional 948,659 shares during the last quarter. 20.35% of the stock is owned by institutional investors.

AstraZeneca Stock Down 0.1%

Shares of NASDAQ:AZN opened at $81.70 on Monday. AstraZeneca PLC has a 1 year low of $61.24 and a 1 year high of $84.30. The company has a market cap of $253.38 billion, a PE ratio of 30.71, a P/E/G ratio of 1.50 and a beta of 0.37. The company has a debt-to-equity ratio of 0.55, a current ratio of 0.86 and a quick ratio of 0.67. The stock's 50-day moving average is $74.90 and its 200 day moving average is $72.73.

AstraZeneca (NASDAQ:AZN - Get Free Report) last announced its quarterly earnings results on Tuesday, July 29th. The company reported $1.09 earnings per share (EPS) for the quarter, meeting analysts' consensus estimates of $1.09. AstraZeneca had a return on equity of 32.84% and a net margin of 14.68%.The company had revenue of $14.46 billion for the quarter, compared to the consensus estimate of $14.08 billion. During the same quarter in the previous year, the business earned $1.24 EPS. AstraZeneca's revenue was up 16.1% compared to the same quarter last year. Sell-side analysts anticipate that AstraZeneca PLC will post 4.51 EPS for the current year.

AstraZeneca Cuts Dividend

The company also recently announced a semi-annual dividend, which will be paid on Monday, September 8th. Shareholders of record on Friday, August 8th will be issued a dividend of $0.505 per share. The ex-dividend date is Friday, August 8th. This represents a dividend yield of 200.0%. AstraZeneca's dividend payout ratio is 37.97%.

Wall Street Analyst Weigh In

Separately, Berenberg Bank set a $97.00 target price on AstraZeneca in a research note on Wednesday, July 9th. Four analysts have rated the stock with a Buy rating and one has given a Hold rating to the stock. According to MarketBeat, the company presently has a consensus rating of "Moderate Buy" and a consensus target price of $86.00.

AstraZeneca Profile

AstraZeneca PLC, a biopharmaceutical company, focuses on the discovery, development, manufacture, and commercialization of prescription medicines. The company's marketed products include Tagrisso, Imfinzi, Lynparza, Calquence, Enhertu, Orpathys, Truqap, Zoladex, Faslodex, Farxiga, Brilinta, Lokelma, Roxadustat, Andexxa, Crestor, Seloken, Onglyza, Bydureon, Fasenra, Breztri, Symbicort, Saphnelo, Tezspire, Pulmicort, Bevespi, and Daliresp for cardiovascular, renal, metabolism, and oncology.

Want to see what other hedge funds are holding AZN? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for AstraZeneca PLC (NASDAQ:AZN - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.